"Desrinitis" is a synthetic topical glucocorticosteroid (GCS). The active substance mometasone has anti-allergic and anti-inflammatory effects. When using the drug in doses that do not cause systemic effects, its local anti-inflammatory effect is manifested. Consider in this article about the drug "Desrinitis" reviews of doctors and consumers.
The drug inhibits the release of inflammatory mediators, increases the production of lipomodulin, which is an phospholipase A inhibitor, and this leads to a decrease in the released arachidonic acid and inhibition of the synthesis of prostaglandins and cyclic endoperoxides. The drug causes the prevention of neutrophil accumulation, a decrease in inflammatory exudate and the production of lymphokines, inhibition of macrophage migration, a decrease in granulation and infiltration processes, a decrease in the formation of chemotaxis, that is, an effect on the late allergy reaction, the development of an instant allergic reaction stops.
This is confirmed by the Desrinit medication by the reviews of doctors - specialists in their field. The composition of the product includes mometasone furoate and excipients.
Pharmacokinetics
Intranasal administration reduces the systemic bioavailability of mometasone fuorate to less than 1%. The active substance that can enter the gastrointestinal tract is absorbed in small amounts and biotransforms actively after the first passage through the liver. About the drug "Desrinitis" reviews of doctors are mostly positive.
Indicated for use with:
- treatment of year-round and seasonal allergic rhinitis in children from 2 years of age and older and adults;
- acute sinusitis, exacerbation of chronic sinusitis in children from twelve years of age and older, as well as adults (including the elderly) as an adjunct to antibiotic treatment;
- treatment of adenoids in children or adult nasal polyposis;
- the prevention of seasonal allergic rhinitis in severe and moderate conditions of children from twelve years of age and older, as well as adults. Carrying out recommended four weeks before the start of the dusting season.
Release form
Metered-dose nasal spray. One bottle contains 140 doses. In the reference book, the form of this medicine in the form of drops did not exist at the time of publication of the drug. Suitable "Desrinitis" for children. Doctors' reviews confirm this.
Method of use and instructions for use
The drug is administered intranasally. The spray contained in the vial is injected into the nose using a special dosing device.
Before using the spray, you need to do 10 test clicks on the dispensing device. After calibration, the drug delivery rate is established, each press ejects a suspension in a volume of 100 mg, which contains 50 μg of mometasone. Before using the drug after a more than 14-day break, the calibration will need to be repeated. Each application should be accompanied by preliminary shaking of the bottle.
Side effects
About the drug "Desrinitis" reviews of doctors indicate the following possible side effects:
- glaucoma;
- hypersensitivity reactions, including shortness of breath and bronchospasm;
- anaphylaxis;
- headache in children and adults;
- angioedema;
- nose bleed;
- burning of the nasal cavity;
- in children, growth retardation, psychomotor hyperactivity, sleep disturbances, anxiety, aggressive behavior, depression can be observed;
- pharyngitis;
- perforation of the nasal septum ;
- a feeling of irritation of the mucous membrane in the nasal cavity;
- a feeling of irritation of the mucous membrane of the pharynx;
- upper respiratory tract infections;
- sneezing
- taste violation;
- violation of smell;
- cataract;
- increased intraocular pressure;
- ulceration of the mucous membrane in the nasal cavity.
Contraindications
The drug "Desrinitis" (reviews of doctors confirm this) is contraindicated in:
- hypersensitivity to mometasone or any component of the drug;
- recent surgery or nasal injury before wound healing, since corticosteroids have an inhibitory effect on healing processes;
- in childhood (with polyposis of the nasal cavity up to 18 years; with exacerbations of chronic sinusitis or its acute form up to 12 years; with year-round and seasonal allergic rhinitis up to 2 years).
Use of the drug during pregnancy and breastfeeding
Specifically, no studies have been conducted on the safe use of Desrinit during pregnancy and lactation. This drug should be prescribed to breastfeeding and pregnant women only if the health benefits of the mother exceed the potential risks to the child or fetus. Newborns whose mothers used GCS during pregnancy must undergo a special examination to identify possible adrenal hypofunction. This is confirmed by the medicine "Desrinitis" reviews of immunologists.
The use of the drug for children
The use of "Desrinitis" is contraindicated in children with polyposis of the nasal cavity up to 18 years; with exacerbation of chronic sinusitis or its acute form up to 12 years; with year-round and seasonal allergic rhinitis up to 2 years. Often used "Desrinitis" with adenoids in children. Reviews of doctors in this regard are positive.
Directions for use
There were no signs of atrophy of the nasal mucosa after using the drug for a year (12 months). A study of biopsy samples of the nasal mucosa revealed the effect of mometasone on the tendency to normalize the histological picture. Long-term use of the drug, like any long-term treatment, involves a periodic examination of the nasal mucosa by an otorhinolaryngologist.
With tuberculosis of the respiratory tract (latent or active); bacterial, systemic viral (including cold sores, Herpes simplex) or fungal infections; long-term treatment through corticosteroids; the presence of untreated local infection of the nasal mucosa, as well as with breastfeeding and pregnancy, the drug should be prescribed with great care.
Treatment with Desrinit is recommended to stop and begin to carry out special therapy with the development of a local fungal infection of the pharynx or nose.
Irritation of the mucous membrane of the pharynx and nasal cavity, which persists for a very long period of time, can be considered an indication for refusing to use the drug. It can also be noted that there was no suppression of the functions of the hypothalamic-pituitary-adrenal system after prolonged use of the drug. This is indicated by reviews about the drug "Desrinitis."
Particular attention is required for patients who have received long-term treatment with glucocorticosteroids, switching to treatment with mometasone. If you cancel the GCS systemic action, then with some probability we can say that this will cause an insufficiency of the adrenal gland, the treatment of which will require appropriate measures.
In some patients, when switching to treatment with mometasone after corticosteroids, symptoms of systemic glucocorticosteroid withdrawal may occur. These include depression, a feeling of fatigue, pain in the muscles and / or joints. Patients should be specifically convinced that treatment with Desrinit is advisable, despite the reduction in the symptoms of damage to the nasal mucosa. Masked (but already existing in the patient) by treatment with systemic glucocorticosteroids, allergic diseases such as eczema and conjunctivitis can be detected by the transition from GCS to local ones.
In the treatment of unilateral polyps; polyps that are associated with cystic fibrosis, and polyps that completely cover the nasal cavity, the safety and effectiveness of Desrinit has not been studied. Bleeding and unilateral polyps that have an irregular shape must be investigated additionally.
Patients receiving therapy through glucocorticosteroids acquire reduced immune reactivity, and therefore they should be warned about an increased risk of infection through contact with sick measles, chicken pox and some other diseases of an infectious nature, as well as the need to consult a specialist if contact with the patient is nevertheless took place.
Long-term use of corticosteroids nasal in large doses can be a catalyst for the development of side effects. However, these effects can occur with a much lesser probability than when systemic corticosteroids are used, and differ in individual patients. Potential systemic effects include Cushing's syndrome, which is characterized by suppression of adrenal function, glaucoma, cataracts, stunting in adolescents and children, and sometimes a number of behavioral and psychological effects, including anxiety, sleep disturbance, aggression or depression, psychomotor hyperactivity.
As for the drug interaction of various drugs with mometasone, no studies have been conducted on this subject.
Nasal spray "Teva Desrinitis": reviews of buyers and doctors
Reviews about the drug are mostly positive. It helps with allergic rhinitis. It is normally tolerated, rarely gives side effects. Helps young children with adenoids, relieves inflammation. The main thing is to follow the instructions for use.